A detailed history of Steward Partners Investment Advisory, LLC transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Steward Partners Investment Advisory, LLC holds 117 shares of SUPN stock, worth $3,725. This represents 0.0% of its overall portfolio holdings.

Number of Shares
117
Previous 117 -0.0%
Holding current value
$3,725
Previous $3,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 15, 2023

SELL
$31.09 - $37.88 $777 - $947
-25 Reduced 17.61%
117 $4,000
Q3 2022

Nov 10, 2022

BUY
$28.79 - $35.41 $719 - $885
25 Added 21.37%
142 $5,000
Q4 2021

Feb 08, 2022

SELL
$26.37 - $34.22 $395 - $513
-15 Reduced 11.36%
117 $3,000
Q2 2021

Aug 13, 2021

SELL
$26.72 - $33.19 $13,360 - $16,595
-500 Reduced 79.11%
132 $4,000
Q1 2021

May 14, 2021

BUY
$24.15 - $31.45 $12,075 - $15,725
500 Added 378.79%
632 $16,000
Q2 2020

Aug 06, 2020

SELL
$17.09 - $24.89 $1,726 - $2,513
-101 Reduced 43.35%
132 $3,000
Q1 2020

Apr 29, 2020

SELL
$14.45 - $24.69 $2,890 - $4,938
-200 Reduced 46.19%
233 $4,000
Q4 2019

Jan 17, 2020

SELL
$19.93 - $29.13 $3,986 - $5,826
-200 Reduced 31.6%
433 $10,000
Q3 2019

Oct 30, 2019

BUY
$25.47 - $33.37 $382 - $500
15 Added 2.43%
633 $17,000
Q2 2019

Jul 25, 2019

BUY
$29.96 - $38.87 $18,515 - $24,021
618 New
618 $20,000
Q4 2018

Jan 15, 2019

SELL
$30.84 - $49.51 $9,776 - $15,694
-317 Closed
0 $0
Q3 2018

Oct 23, 2018

BUY
$42.7 - $56.55 $8,540 - $11,310
200 Added 170.94%
317 $16,000
Q1 2017

Nov 22, 2017

BUY
N/A
117
117 $3,000

Others Institutions Holding SUPN

About SUPERNUS PHARMACEUTICALS, INC.


  • Ticker SUPN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 53,495,300
  • Market Cap $1.7B
  • Description
  • Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...
More about SUPN
Track This Portfolio

Track Steward Partners Investment Advisory, LLC Portfolio

Follow Steward Partners Investment Advisory, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Steward Partners Investment Advisory, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Steward Partners Investment Advisory, LLC with notifications on news.